DFFN - ディフュ―ジョン・ファ―マシュ―ティカルズ （Diffusion Pharmaceuticals Inc.） ディフュ―ジョン・ファ―マシュ―ティカルズDFFNのチャート
DFFNの企業情報
| symbol | DFFN |
|---|---|
| 会社名 | Diffusion Pharmaceuticals Inc （ディフュ―ジョン・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Diffusion Pharmaceuticals Inc. formerly RestorGenex Corporation is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments including radiation therapy and chemotherapy. The Company''s lead product candidate transcrocetinate sodium also known as trans sodium crocetinate (TSC) is used in various cancer types in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company''s Diffusion''s technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate TSC with standard-of-care radiation and chemotherapy regimens thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types with an initial focus on primary brain cancer (glioblastoma or GBM) pancreatic cancer and brain metastases. ディフュ―ジョン・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、がん腫瘍の治療に使用するトランスクロセチン酸ナトリウム(TSC)の開発に従事する。がん細胞に対する放射線治療や化学療法の効果を上げるためにTSCを使用する。また、TSCはにきびなど皮膚の疾患の治療にも使用される。本社はバ―ジニア州シャ―ロッツビル。 Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most. Diffusion's lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine's most intractable and difficult-to-treat conditions. In addition to TSC, Diffusion's product candidate DFN-529, a novel, allosteric PI3K/Akt/mTOR Pathway inhibitor, is in early-stage development. |
| 本社所在地 | 1317 Carlton Avenue Suite 200 Charlottesville VA 22902 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 434-220-0718 |
| 設立年月日 | 34669 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 11人 |
| url | www.diffusionpharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/dffn |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -12.11949 |
| 終値（lastsale） | 0.409 |
| 時価総額（marketcap） | 20683948.409 |
| 時価総額 | 時価総額（百万ドル） 19.72308 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 6.78838 |
| 当期純利益 | 当期純利益（百万ドル） -11.09095 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Diffusion Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders increased from $7M to $14.3M. Higher net loss reflects FV/Uls Adjust on Derivatives for Hedging decrease from $10.5M (income) to $0K Depreciation increase from $12K to $55K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.54 to -$0.33. |
DFFNのテクニカル分析
DFFNのニュース
Diffusion Pharmaceuticals (NASDAQ:DFFN) Coverage Initiated by Analysts at StockNews.com 2023/04/03 06:20:59 EIN News Pharmaceuticals
… coverage on shares of Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) … owned by institutional investors. Diffusion Pharmaceuticals Company Profile (Get Rating) Diffusion … '' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat …
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CNXC, DFFN 2023/04/02 13:47:00 GlobeNewswire
NEW YORK, April 02, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
DIFFUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Diffusion Pharmaceuticals Inc. - DFFN 2023/04/01 00:01:00 Business Wire
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Diffusion Pharmaceuticals Inc. (the “Company”) (NasdaqCM: DFFN) with EIP Pharma Inc. pursuant to which Diffusion shareholders will end up owning 22.75% of the total number of outstanding shares of the combined company, subject to adjustment. KSF is seeking to determine whether the merger and the process that
Diffusion to merge with EIP Pharma in all-stock deal 2023/03/30 13:32:18 Seeking Alpha
Diffusion Pharmaceuticals (DFFN) is merging with privately held EIP Pharma in an all-stock deal to focus on neuro diseases. Read more here
EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases 2023/03/30 11:00:00 GlobeNewswire
Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies
Diffusion to undertake strategic review, options may include company sale 2022/10/25 10:57:36 Seeking Alpha
Diffusion Pharmaceuticals (DFFN) said it will undertake a strategic review to evaluate options which could include a sale of the company.As part of its ongoing efforts to…
DFFN stock raised to Buy at H.C. Wainwright after Q2 update on lead asset (NASDAQ:DFFN) 2022/08/16 16:58:28 Seeking Alpha
H.C. Wainwright upgraded clinical-stage biotech Diffusion Pharma (DFFN) to Buy from Neutral on Tuesday, citing the company''s Q2 2022 update on its lead candidate Trans Sodium…
H.C. Wainwright Upgrades Diffusion Pharma to Buy 2022/08/16 10:26:02 Investing.com
https://www.investing.com/news/pro/hc-wainwright-upgrades-diffusion-pharma-to-buy-432SI-2873513
Diffusion Pharmaceuticals GAAP EPS of -$2.06 misses by $0.02 2022/08/12 06:24:44 Seeking Alpha
Diffusion Pharmaceuticals press release (DFFN): Q2 GAAP EPS of -$2.06 misses by $0.02.As of June 30, 2022, Diffusion had $28.5M in cash, cash equivalents, and marketable…
Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update 2022/08/11 22:48:00 GlobeNewswire
• Aligned with FDA on Design of Phase 2 GBM Trial of TSC; Initiation Expected by End of 2022 • Reported Positive Effects in TSC Altitude Trial • Ended Quarter with $28.5 million in Cash, Cash Equivalents and Marketable Securities • Expected Cash Runway into First Quarter of 2024
DFFN stock raised to Buy at H.C. Wainwright after Q2 update on lead asset (NASDAQ:DFFN) 2022/08/16 16:58:28 Seeking Alpha
H.C. Wainwright upgraded clinical-stage biotech Diffusion Pharma (DFFN) to Buy from Neutral on Tuesday, citing the company''s Q2 2022 update on its lead candidate Trans Sodium…
H.C. Wainwright Upgrades Diffusion Pharma to Buy 2022/08/16 10:26:02 Investing.com
https://www.investing.com/news/pro/hc-wainwright-upgrades-diffusion-pharma-to-buy-432SI-2873513
Diffusion Pharmaceuticals GAAP EPS of -$2.06 misses by $0.02 2022/08/12 06:24:44 Seeking Alpha
Diffusion Pharmaceuticals press release (DFFN): Q2 GAAP EPS of -$2.06 misses by $0.02.As of June 30, 2022, Diffusion had $28.5M in cash, cash equivalents, and marketable…
Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update 2022/08/11 22:48:00 GlobeNewswire
• Aligned with FDA on Design of Phase 2 GBM Trial of TSC; Initiation Expected by End of 2022 • Reported Positive Effects in TSC Altitude Trial • Ended Quarter with $28.5 million in Cash, Cash Equivalents and Marketable Securities • Expected Cash Runway into First Quarter of 2024
Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference 2022/05/17 11:30:00 GlobeNewswire
CHARLOTTESVILLE, Va., May 17, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that Robert Cobuzzi, Jr., Ph.D., the Company’s President and Chief Executive Officer, will be presenting at the H.C. Wainwright Global Investment Conference being held at the Fontainebleau Miami Beach Hotel from May 23-26, 2022.